FDA Postmarket Cybersecurity for Cardiovascular Devices
FDA postmarket cybersecurity for pacemakers, ICDs, monitors, and remote follow-up - SBOM monitoring, CVD program, and reviewer-ready PMA Annual Reports.
Last reviewed March 2026 · Reviewed against the FDA Feb 3, 2026 final premarket cybersecurity guidance.
Postmarket cybersecurity for cardiovascular devices is the canonical use case in FDA's postmarket guidance and AAMI TIR97 - long lifetimes, large fleets, multi-element architectures, and a public history of disclosed vulnerabilities. Our postmarket program for this segment covers the four things reviewers and CISA both expect to see: SBOM monitoring, a Coordinated Vulnerability Disclosure (CVD) program, postmarket threat-landscape surveillance, and a documented update / remediation pathway for fielded devices.
We operate ongoing SBOM monitoring across implant, programmer, home monitor, and cloud against NVD/OSV/GHSA, with auto-generated VEX drafts your team triages - the day-one VEX is not enough for a 10-year fleet. We stand up or operate a CVD program aligned to ISO/IEC 29147 and 30111, with clear intake, triage, and disclosure timelines, and integration with FDA and CISA disclosure channels. We track postmarket cyber threat intelligence specific to your device class (cardiac CIEDs are a high-attention surface for security researchers) and surface what matters. And we maintain the documented update pathway - which devices in the field can take which patches, who's authorized, and how that's evidenced in PMA Annual Reports and Section 524B postmarket submissions. We've operated this kind of program for cardiac OEMs through public CVE disclosures.
Layers we exercise in this engagement
The cardiovascular system, from the outermost cloud and clinician surfaces down to the device itself. Highlighted layers are exercised by this fda postmarket cybersecurity.
- 01Cloud backend Tested
- 02Home monitor fleet Tested
- 03Programmer fleet Tested
- 04Implant fleet Tested
- 05Vulnerability intake (CVD) Tested
Layers shown outermost (top) to innermost (bottom). Dashed rows are part of the surrounding system but out of scope for this view.
FDA Postmarket Cybersecurity engagement, end to end
Four phases, fixed fee, scoped to cardiovascular architecture from kickoff onward.
-
01
Scope + kickoff
Architecture review, attack-surface walkthrough, and threat-model alignment with your team. Written scope in 24 hours.
-
02
Threat-model alignment
Every STRIDE entry in your threat model is matched to a planned test case so reviewers see one-to-one coverage.
-
03
Test execution
Device, cloud, mobile, BLE/RF, and OTA channels exercised in parallel by senior engineers - not a single web-app scan.
-
04
Reviewer-ready report + retest
eSTAR-format report with findings, CVSS, remediation, and unlimited retests until every finding is closed.
What we see in Cardiovascular fda postmarket cybersecurity
The patterns we hit in this segment, this service, again and again.
-
Day-one SBOM not maintained against new CVEs
Submitted SBOM is a snapshot. New high-severity CVEs land with no exploitability determination; reviewer asks for current state.
-
No formal CVD program
Researcher contact is a generic security@ alias with no SLA. Disclosure handled ad-hoc; no ISO/IEC 29147 alignment.
-
Field update pathway undefined for older fleet
Newer generation supports OTA; older deployed generation does not. No documented strategy for the older fleet's CVE response.
-
Postmarket threat surveillance ad-hoc
No structured intel intake for the segment. Public researcher disclosures discovered late.
Public cardiovascular cybersecurity history
Recalls, CISA ICS-MA advisories, and disclosed research that shape what reviewers ask about in this segment - and what our scope is built to cover.
"Blue Goat Cyber helped us navigate our first end-to-end cybersecurity testing for our wearable medical device. Their communication was excellent, their timeline exceeded expectations, and their report helped us achieve FDA clearance without any additional questions. It was a truly seamless experience."
Standard FDA Postmarket Cybersecurity deliverables
The same deliverables the parent FDA Postmarket Cybersecurity service ships with - tuned to your cardiovascular architecture.
- TPLC Partnership: Annual retainer covering one product line through Total Product Lifecycle - SBOM monitoring, CISA-KEV tracking, full CVD process operation, quarterly penetration tests, and ongoing FDA/EU regulatory updates. One predictable fee, one accountable team, zero gaps between cleared release and end-of-support.
- SBOM monitoring: Section 524B requires manufacturers to maintain and update SBOMs continuously. We track every component for newly disclosed CVEs and flag them before they become reportable vulnerabilities.
- CVD program (Coordinated Vulnerability Disclosure): We manage the full CVD process - researcher intake, triage, fix timeline, and FDA notification - so your team doesn't face a public disclosure event without a prepared response. FDA's 30-day notification requirement is built into every engagement.
- Threat monitoring: We proactively monitor your device's ecosystem 24/7 - not alert-driven, team-driven.
- Incident response: Response plans aligned with FDA's 30-day vulnerability notification requirement - with audit-ready documentation from day one.
- Patch validation: Every patch goes through validation testing before deployment - so you can demonstrate to FDA that the fix didn't introduce new risk.
What lands in your eSTAR submission
Reviewer-format documents ready to drop straight into the cybersecurity attachments of your submission - no reformatting on your side.
- TPLC Partnership: Annual retainer covering one product line through Total Product Lifecycle - SBOM monitoring, CISA-KEV tracking, full CVD process operation, quarterly penetration tests, and ongoing FDA/EU regulatory updates. One predictable fee, one accountable team, zero gaps between cleared release and end-of-support.
- SBOM monitoring: Section 524B requires manufacturers to maintain and update SBOMs continuously. We track every component for newly disclosed CVEs and flag them before they become reportable vulnerabilities.
- CVD program (Coordinated Vulnerability Disclosure): We manage the full CVD process - researcher intake, triage, fix timeline, and FDA notification - so your team doesn't face a public disclosure event without a prepared response. FDA's 30-day notification requirement is built into every engagement.
- Threat monitoring: We proactively monitor your device's ecosystem 24/7 - not alert-driven, team-driven.
- Incident response: Response plans aligned with FDA's 30-day vulnerability notification requirement - with audit-ready documentation from day one.
Standards that apply
The Cardiovascular baseline, plus the call-outs that matter for fda postmarket cybersecurity in this segment.
Segment-specific call-outs
AAMI TIR97 + FDA postmarket cybersecurity guidance
Cardiac fleets are explicitly the use case these documents anticipate. Reviewers expect direct alignment.
ISO/IEC 29147 and 30111
CVD program structure reviewers and CISA both reference. We align the program to these as standard.
What's not in scope
We scope tightly on purpose. These items are either out-of-scope by design or belong in a separate engagement - we'll tell you up front, not after kickoff.
- Hospital enterprise IT network penetration testing
- Clinical efficacy or human-factors validation
- Physical security of manufacturing sites
- Source-code review (unless explicitly added as a separate engagement)
FDA Postmarket Cybersecurity for Cardiovascular - FAQs
The questions buyers in this segment actually ask before scoping a fda postmarket cybersecurity engagement.
Go deeper on Cardiovascular and postmarket
A practical, ungated buyer's guide for medical device manufacturers evaluating cybersecurity partners, what goes wrong, why it costs you, and what to demand from your next engagement. Aligned to the FDA February 2026 premarket guidance.
A practical, ungated guide to the threat modeling gaps that trigger FDA cybersecurity questions in 510(k), De Novo, and PMA submissions - and exactly how to close them before reviewers find them.
The most common cybersecurity deficiencies in 510(k), De Novo, and PMA submissions, what triggers each one and how to fix it before you file. Aligned to the FDA February 2026 final guidance and Section 524B.
What happens if you fail an FDA cybersecurity inspection: the 483-to-consent-decree enforcement ladder and the commercial fallout for device makers.
How to document update cadence for an FDA 524B submission: the regular cycle and the out-of-cycle expedited path reviewers expect under 524B(b)(2)(B).
FDA Section 524B applies to any new premarket submission for a cyber device, including legacy platforms. What attaches, what postmarket rules cover the rest.
Other engagements for Cardiovascular
Teams in this segment commonly bundle these alongside fda postmarket cybersecurity.
Keep going
Scope a FDA Postmarket Cybersecurity engagement for your cardiovascular program.
A 30-minute call with a senior engineer who has done this in cardiovascular before - not a sales rep.